Date: 2017-03-17
Type of information: R&D agreement
Compound: G protein-coupled receptor (GPCR)
Company: Daiichi Sankyo (Japan) Heptares Therapeutics (UK)
Therapeutic area: CNS diseases
Type agreement: research development
Action mechanism: G protein-coupled receptor (GPCR)
Disease: pain
Details: * On March 13, 2017, Daiichi Sankyo announced that it has entered with Heptares Therapeutics, a wholly owned subsidiary of Sosei Group Corporation, into a drug discovery and licensing agreement focused on a single G protein-coupled receptor (GPCR) nominated by Daiichi Sankyo that plays a crucial role in relieving pain. Under the terms of the agreement, Heptares will apply its proprietary StaR® (stabilised receptor) technology to engineer thermally stabilised forms of the GPCR as the basis for the drug discovery programme. Heptares will also employ advanced structural biology and rational drug design approaches, X-ray crystallography and fragment screening to delineate the GPCR's structure and to generate lead candidates. Daiichi Sankyo will also participate in lead generation and in vivo models. Daiichi Sankyo will be eligible to receive exclusive global rights to develop, manufacture and commercialize novel, small molecules discovered by Heptares focused on the nominated GPCR. In return, Heptares will receive an upfront payment, research funding, and is eligible to receive additional research, development and commercialization milestone payments. In addition, Heptares will be eligible to receive royalties on net sales of products resulting from the alliance.
Financial terms:
Latest news:
